Biovica is raising capital to scale up with pharma companies

Imaging scans are currently used to assess whether a cancer treatment is working. In practice, this often means months of anxious waiting to find out what the next scan will show.

“We are actively working to change the standard for cancer care, to save lives and improve patients’ quality of life. With DiviTum TKa, we can detect within the first few weeks of treatment whether tumour cell division has slowed down. Faster, regular test results can help oncologists intervene earlier and adjust treatment,” says Theis Kipling, CEO of Biovica.

The blood-based test DiviTum TKa measures the activity of an enzyme called thymidine kinase. A high result indicates that tumour cells are dividing rapidly, whilst low activity can be linked to the drug being effective and a lower risk of the tumour growing. Biovica is focused on metastatic breast cancer, and the technology is already used in the US to monitor treatment. The aim is to build enough evidence for DiviTum TKa to be included in US treatment guidelines.

Pharma companies use the test in their studies

Biovica is also investing heavily in its Pharma Services business. This involves providing tests and analyses for pharma companies, who use DiviTum TKa to assess the effects of treatments under development. For example, DiviTum is used to gain a better understanding of how a cancer drug affects the tumour, and to support decisions on which dose produces the best biological effect.

Several companies have also shown interest in DiviTum TKa as a potential tool for selecting patients for clinical studies.

“If we can select patients in advance whose blood tests suggest a good response to a particular treatment, we can protect the hundreds of millions that the drug company invests in clinical development. It also sets the stage for a positive study outcome,” says Theis Kipling, adding:

“If that hypothesis proves correct, DiviTum could become a companion diagnostic — a test used alongside a specific drug. With the help of drug companies, we could then bring our technology to a global market. That is the next concrete milestone we are working towards.”

Pharma Services is expanding ahead of the rights issue

Between May and July 2026, Biovica’s revenue grew by 56 per cent compared with the same period last year. Revenue from Pharma Services increased by 95 per cent. Theis Kipling, who became CEO in early May, has focused on sharply reducing costs and extending how long the company’s cash will last, to strengthen its financial position.

“The rights issue, which is already fully covered by subscription commitments and an underwriting guarantee from our main shareholder, is part of this work. The proceeds will support our commercial rollout in the US and the expansion of Pharma Services,” says Theis Kipling.